CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March

NEWARK, Calif., March 05, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 30^th Annual ROTH Conference, the H.C. Wainwright 2^nd Annual NASH Investor Event, and the Oppenheimer & Company 28^th Annual Healthcare Conference.

30^th Annual ROTH Conference 2018
Date:                    Monday, March 12
Time:                    9am Pacific Time
Location:              Ritz Carlton, Laguna Niguel, CA

H.C. Wainwright 2^nd Annual NASH Investor Event
Date:                    Monday, March 19
Time:                    9:20am Eastern Time
Location:              St. Regis Hotel, New York, NY
Webcast:             http://ir.cymabay.com/events

Oppenheimer & Company 28^th Annual Healthcare Conference
Date:                    Tuesday, March 20
Time:                    9:10am Eastern Time
Location:              Westin New York Grand Hotel, NY
Webcast:             http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]